NCT06912477 Endothelial Dysfunction for Prognosis In Patients With preeClampSia
| NCT ID | NCT06912477 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Heidelberg University |
| Condition | Preeclampsia (PE) |
| Study Type | OBSERVATIONAL |
| Enrollment | 385 participants |
| Start Date | 2025-05-08 |
| Primary Completion | 2026-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 385 participants in total. It began in 2025-05-08 with a primary completion date of 2026-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Preeclampsia is a pregnancy-specific hypertensive disorder and can progress rapidly to severe adverse outcomes affecting both the mother and the fetus. Endothelial and microcirculatory dysfunction mediate systemic preeclampsia-related organ dysfunctions. Changes in endothelial and vascular function in preeclampsia have been demonstrated through reduced flow-mediated vasodilation as a result of reduced availability of nitric oxide, which potentially persists up to several years postpartum. Hyperspectral imaging is a new innovative technology that allows to assess the peripheral microcirculation and perfusion non-invasively and contactless, but has never been evaluated in the context of preeclampsia before. This EPICS project (Endothelial dysfunction for Prognosis In patients with preeClampSia) is a prospective observational study and aims to investigate hyperspectral imaging as a new potential diagnostic and prognostic marker in preeclampsia.
Eligibility Criteria
Inclusion Criteria: * singleton pregnancies * Age ≥ 18 years * Patient's ability to provide consent * written informed consent Exclusion Criteria: * Lack of consent * Language barrier * Dark to very dark skin type * Severe fetal chromosomal/genetic/structural anomalies * Laboratory changes in LDH, creatinine, or platelets due to other causes (e.g., isolated thrombocytopenia, e.g., immune thrombocytopenia, carcinoma)
Contact & Investigator
Dr. med. Alexandra von Au
PRINCIPAL INVESTIGATOR
University Heidelberg
Frequently Asked Questions
Who can join the NCT06912477 clinical trial?
This trial is open to female participants only, aged 18 Years or older, studying Preeclampsia (PE). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06912477 currently recruiting?
Yes, NCT06912477 is actively recruiting participants. Contact the research team at anna.scholz@med.uni-heidelberg.de for enrollment information.
Where is the NCT06912477 trial being conducted?
This trial is being conducted at Heidelberg, Germany.
Who is sponsoring the NCT06912477 clinical trial?
NCT06912477 is sponsored by Heidelberg University. The principal investigator is Dr. med. Alexandra von Au at University Heidelberg. The trial plans to enroll 385 participants.